Navigation Links
Cytopia and Other Progen Shareholders Maintain Call for Meeting
Date:2/8/2009

ed and merger terms are discussed and agreed.

Combine Meetings

While the requisitioning shareholders hold the number of shares (5%) necessary to call the meeting, there is far wider support from Progen shareholders for the new choice resolutions being proposed. A general meeting to achieve this should be held at the same time any merger with Avexa is considered to allow the Progen shareholders to choose between the two alternatives in the one meeting. Cytopia, in conjunction with another 18% of Progen shareholders, has formally requested Progen to align the holding of the two meetings and it is believed the same request has been made directly to the company by others.

Progen has advised that a combined meeting is not possible because of the requirement in the company's constitution for 35 business days' notice for directors' nominations. Accordingly, the general meeting to consider the Avexa merger should be delayed to enable all of the proposed resolutions to be considered together. This proposal will be put to the Progen board at the same time as the appropriate substantiation supporting the validity of the resolutions is supplied.

Proposed Progen and Avexa merger

The Progen board has released a notice of general meeting at which shareholders will be asked, amongst other things, to vote on the proposed merger with Avexa.

  • After adopting a high-risk strategy of electing to fund a Phase III clinical trial, raising $100m at approximately $5 per share, then cancelling the trial, the board is now asking shareholders to support the same strategy again in a different disease area.
  • It has advised that the merged entity would have combined cash of around $60 million, but $155 million would be needed to complete the four year Phase III program for the HIV drug candidate, leaving a $95 million shortfall.

'/>"/>
SOURCE Cytopia Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Presentation on Cytopias JAK2 Inhibitor Program in Myeloproliferative Disorders
2. Cytopia Strengthens Scientific Team With US-Based Drug Development Specialist
3. Cytopia Presentation on JAK2 Inhibitor at American Association for Cancer Research
4. Microtest Labs Offers Free Microbial Identification Testing, Free Shipping on Other Tests, to MD&M West Attendees
5. REXIN-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009)
6. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
7. GeneGo Renews Its Agreement With Bayer Schering Pharma AG for Another Three Years
8. BioLife Solutions Completes Safety Studies on HypoThermosol(R) and CryoStor(TM)
9. Prostate Cancer Patient in Montpellier Becomes First Cancer Patient in France Treated with Varians RapidArc(TM) Radiotherapy
10. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
11. South Africas Minister of Minerals and Energy Welcomes Denham Capital Investment in BioTherm Energy to Develop Power Generation Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... its newly developed Bruton,s tyrosine kinase (BTK) inhibitor ... The results of these preclinical evaluations have been ... The feedback received from the Agency is supportive ... Additional preclinical work is required to begin a ...
(Date:2/27/2015)... Australia , Feb. 27, 2015 Bionomics ... from the DisrupTOR-1 trial of BNC105 in patients with ... in Orlando, Florida . The data ... of the City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and ...
(Date:2/27/2015)... , Feb. 27, 2015   PureTech , ... inventing and commercializing disruptive products and technologies in the ... Viehbacher , former CEO and Member of the Board ... "It,s has been a pleasure to ... excited that we will be working together more closely ...
(Date:2/26/2015)... Synageva BioPharma Corp. (NASDAQ: GEVA ... rare disorders, today reported 2014 full year financial ... and financial guidance.  Synageva,s management team will host ... to review the financial results and provide a ... by telephone, please dial (877) 445-4603 for U.S. ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... Researchers at Northwestern University have created a new ... invisible in the terahertz range. Though this ... the visible spectrum, it could have implications in ... by Cheng Sun, assistant professor of mechanical engineering ...
... This release is available in German . ... and MIT professor Ron Weiss have successfully incorporated a ... recognizes certain cancer cells using logic combinations of five ... (Kobi) Benenson, Professor of Synthetic Biology at ETH Zurich, ...
... N.C. Researchers at Duke University Medical Center, Beth Israel ... approach to HIV vaccine design that uses an altered form ... The researchers showed that they could design HIV envelopes that ... an enhanced immune response in an animal model. Immature B ...
Cached Biology Technology:Hiding objects with a terahertz invisibility cloak 2Profiler at the cellular level 2Profiler at the cellular level 3New HIV vaccine approach targets desirable immune cells 2New HIV vaccine approach targets desirable immune cells 3
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
(Date:2/5/2015)... --  Epic Sciences , a precision diagnostics company dedicated to ... Prahalad , Ph.D., president and CEO, is scheduled to present ... Silicon Valley, which is taking place at the Computer History ... January 26-28, 2015. Dr. Prahalad will give ... year, Epic Sciences was a finalist in the PMWC,s Most ...
(Date:2/5/2015)... 28, 2015 Research and Markets ... the "Global Biometrics Market (2014-2020): Market Forecast ... report to their offering. , ... is anticipated to overtake ... increasing government spending towards IT security, government biometric ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
... reliable, and reversible. It would need to be long ... in BioMed Central,s open access journal Reproductive Biology ... to reduce sperm counts of male rats to levels ... potential as a male contraceptive was first reported nearly ...
... A team of UCLA scientists has found that the pathogen ... human immune system by inhibiting the antimicrobial responses important to ... laboratory studies of its kind, researchers discovered that the leprosy ... evade immune activity that is dependent on vitamin D, a ...
... team of biologists at the University of York has made ... attacks the body. The discovery could help scientists target treatments ... 100,000 people every year. , The disease is caused by ... colonise the intestine usually after consumption of contaminated water or ...
Cached Biology News:Stealthy leprosy pathogen evades critical vitamin D-dependent immune response 2Stealthy leprosy pathogen evades critical vitamin D-dependent immune response 3Scientists reveal how cholera bacterium gains a foothold in the gut 2
MOUSE ANTI NEUROFILAMENTS 140+160 KD...
RAT ANTI RAT RT1Au (CLASS I POLYMORPHIC) Immunogen: AO lymphoid cells...
MOUSE ANTI SIMIAN VIRUS 5 Immunogen: Simian virus 5...
... is collected from fasted mixed breed, mixed sex ... Anticoagulants: N-02: Citrate N-04: ... N-08: Potassium Oxalate N-10: EDTA ... ACD N-07: CPD N-09: ...
Biology Products: